Symptomatic intracranial haemorrhage/haemorrhagic transformation of the cerebral infarct during treatment period (range 6 days to 16 days)⁹ · acute ischaemic stroke
Low‐molecular‐weight heparins or heparinoids showed no clear difference in symptomatic intracranial haemorrhage/haemorrhagic transformation of… compared with unfractionated heparin (low certainty).
1 finding from 1 review
Death or dependency · people with acute stroke
Glyceryl trinitrate (GTN) showed no clear difference in death or dependency (mRS>2), end of trial (90 days) compared with no GTN (high certainty).
1 finding from 1 review
Death by end of trial · people with acute stroke
Glyceryl trinitrate (GTN) showed no clear difference in death, end of trial (90 days) compared with no GTN (high certainty).
1 finding from 1 review
Quality of life, end of trial (90 days) · people with acute stroke
1 finding from 1 review
Adverse effects: headache · people with acute stroke
Glyceryl trinitrate (GTN) leads to higher adverse event: Headache, on treatment (7‐12 days) compared with no GTN (high certainty).
1 finding from 1 review
Intervention not reported
Change in total calories (Kcal/day): at 12 months · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Change in total protein (g/day): at 12 months · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Change in total fat (g/day): at 12 months · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Length of initial hospital stay (days) · people with stroke
The intervention probably leads to higher length of initial hospital stay (days) (moderate certainty).
1 finding from 1 review
Mortality before hospital discharge · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death before discharge ‐ Studies with entry before 3 days based on… compared with control (high certainty).
2 findings from 1 review
Neurodevelopmental disability · respiratory failure in preterm infants
Inhaled NO showed no clear difference in neurodevelopmental disability ‐ Studies with entry after 3 days… compared with control (moderate certainty).
2 findings from 1 review
Death or bronchopulmonary dysplasia · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry… compared with control (high certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry… compared with control (high certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · respiratory failure in preterm infants
Inhaled NO showed no clear difference in intraventricular haemorrhage (grade 3 or 4) ‐ Studies with entry… compared with control (high certainty).
1 finding from 1 review
Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).
1 finding from 1 review
Major bleeding · patients with venous thromboembolism.
LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).
1 finding from 1 review
Mean days in treatment · Adults with opioid dependence
1 finding from 1 review
Mean days in treatment (with varying scheduled duration) · Adults or adolescents with opioid dependence
Buprenorphine probably leads to higher mean days in treatment (with varying scheduled duration) compared with alpha2‐adrenergic agonists (moderate certainty).
1 finding from 1 review
Intervention not reported
Length of NICU stay (days) · neonates requiring intubation and ventilation
1 finding from 1 review
Intervention not reported
Poor neurological outcome by 28 days' postnatal age · neonates requiring intubation and ventilation
The intervention showed no clear difference in poor neurological outcome by 28 days' postnatal age (moderate certainty).
1 finding from 1 review